Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_1
4
80%
Ph phase_2
1
20%

Phase Distribution

4

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
4(80.0%)
Phase 2Efficacy & side effects
1(20.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (80.0%)
Phase 21 (20.0%)

Trials by Status

completed360%
terminated240%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

A Study of E7820 in People With Bone Marrow (Myeloid) Cancers

NCT05024994
terminatedphase_1

FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer

NCT01133990
completedphase_1

An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors

NCT01773421
terminatedphase_1

Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

NCT01347645
completedphase_1

Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma

NCT00078637

Clinical Trials (5)

Showing 5 of 5 trials
NCT05024994Phase 2

A Study of E7820 in People With Bone Marrow (Myeloid) Cancers

Completed
NCT01133990Phase 1

FOLFIRI Alone Versus FOLFIRI Plus Bevacizumab Versus FOLFIRI Plus E7820 as Second-Line Therapy in Patients With Locally Advanced or Metastatic Colorectal Cancer

Terminated
NCT01773421Phase 1

An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors

Completed
NCT01347645Phase 1

Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer

Terminated
NCT00078637Phase 1

Dosing and Safety Study of E7820 in Patients With a Malignant Solid Tumor or Lymphoma

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5